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Abstract
Background: Hereditary spastic paraparesis (HSP) is a rare neurodegenerative condition characterized by slowly
progressive spastic weakness of the lower limbs and urinary sphincter dysfunction. Complex HSP involves additional
neurologic symptoms and signs like ataxia, extra pyramidal signs, polyneuropathy, and cognitive decline. Little is
known about the disease burden for adults with HSP beyond the described core symptoms.
Methods: A cross-sectional survey of 108 adults aged 30 years and older (Mage = 57.7 years, SD = 11.5, range 30
to 81; 54.2 % females) recruited from a national center of expertise for rare disorders and a patient advocacy
organization in Norway. Self-report data from the HSP sample was compared to self-report data from a large
Norwegian population study, HUNT3 (N = 46,293), covering health-related variables such as overall life satisfaction,
mental wellbeing, memory function, perceived pain, and co-morbid diseases. In addition, the HSP sample reported
specific items developed for this study in co-operation with the patient advocacy organization.
Results: The HSP sample more frequently lived alone. Overall, the HSP sample reported lower life satisfaction,
lower mental wellbeing and lower social support, as well as poorer memory and sleep, compared to controls.
Furthermore, the HSP sample more frequently reported musculoskeletal pain, constipation, and urinary incontinence
compared to controls. There was no difference between samples in frequency of physical activity and alcohol and
tobacco use. Men with HSP reported higher impact of HSP, lower life satisfaction, and less ability to perform activities
of daily living compared to women with HSP.
Conclusions: Adults with HSP experience disease burden on a larger number of areas than previously documented,
and men with HSP may represent a particularly vulnerable group.
Background
The term hereditary spastic paraparesis (HSP) is used to
describe a group of neurodegenerative conditions with a
high degree of clinical and genetic heterogeneity [1].
HSP can be divided into “pure” and “complex” forms [1,
2]. Pure forms are characterized by slowly progressive
spastic weakness in the lower limbs, and urinary sphinc-
ter dysfunction. In complex HSP, an additional wide
range of neurological features including ataxia, extra
pyramidal signs, epilepsy, mental retardation, dementia,
and peripheral nerve involvement occurs [1]. In pure
HSP, lifespan is not affected [3]. Early disease debut is
most often associated with slow progression of the
disease, with only a small proportion of affected per-
sons reporting wheelchair use in older age. Late on-
set, however, tends to imply rapid progression and
loss of walking ability from around the age of 60 years
and onwards [2, 4, 5].
Several modes of inheritance of HSP have been de-
scribed, both autosomal dominant, recessive, X linked,
or maternal [6]. Pure HSP is mostly inherited in an
autosomal dominant manner, whereas complicated
forms of HSP tend to be inherited in an autosomal re-
cessive manner [7]. To date, 59 different spastic paraple-
gia genes are known [8]. Prevalence, based on studies
from 16 countries, is estimated to be about 1.8:100 000
[9]. In Norway, where the current survey took place, the
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estimated combined prevalence of pure and complex
HSP has been reported to be 7.4:100 000 [10].
Bladder dysfunction has been described in older adults
with HSP [11–13]. A handful of studies have shown dis-
ease progression correlates with more severe cognitive
impairment [14–17]. The various medical issues that
may affect persons with HSP could influence their per-
ceived quality of life (QoL), as well as their psychological
and social functioning. Although it is well documented
that physical disease, including neurodegenerative disor-
ders, impacts quality of life [18, 19], little is known about
the quality of different areas of life for persons affected
by HSP. Three studies have investigated QoL and/or
psychosocial functioning in adults affected by HSP. In
an Estonian study, QoL was found to be significantly
lower in 49 persons with HSP aged 20 to 70 years com-
pared to 549 healthy controls, except for the mental
health domain [20]. This study did not distinguish be-
tween pure and complex forms of HSP. In a German
study, physical aspects of health-related QoL were more
severely affected than mental aspects in a sample of 143
HSP patients with a mean age of 48 years. However,
both spasticity and reduced mobility was associated with
lower physical and mental scores. Complex HSP and
disease severity predicted lower QoL. Furthermore, both
physical and mental scores were lower in patients with
complex HSP than in those with pure HSP [21]. In a
Brazilian study of 30 HSP patients with the SPG4 gene
mutation and a mean age of 48 years, HSP patients re-
ported more depression, pain, and fatigue compared to
healthy controls [22].
Beyond these presented findings, there has been lim-
ited scientific effort to identify the range of symptoms
that may affect persons with HSP. The present study is a
broad survey of health and everyday life domains among
persons with HSP, including life satisfaction, mental
wellbeing, social support, problems with sleep, memory,
pain, gastrointestinal/urinary functioning, and ability to
perform activities of daily living (ADL). We applied five
methodological features to increase interpretability of
our findings. First, we recruited a large sample of
persons with HSP to increase generalizability to the gen-
eral HSP population. Second, we recruited our sample
through a patient advocacy organization and a resource
center for rare disorders, and not from a hospital setting,
thereby increasing chances of also examining individuals
with fewer symptoms. Third, we developed areas of in-
vestigation in co-operation with board members from a
HSP patient advocacy organization to target our examin-
ation to symptom areas relevant for persons with HSP.
Fourth, we applied a number of health-related questions
drawn from a large population study, to compare our
HSP data to those from a population-based control
group. Fifth, we examined potential differences in the




The sample comprised 108 persons with HSP recruited
from two sources. The majority (61 %) was recruited
from the register of The National Patients’ Association
for Hereditary Ataxia and Spastic Paraplegia (NASPA).
The remaining sample (39 %) was recruited from the
database of Frambu Resource Centre for Rare Disorders
(Frambu). Frambu is one of nine state-financed centers
of expertise administrated by the Norwegian National
Advisory Unit on Rare Disorders. Registration in
Frambu’s patient database is voluntary and based on pa-
tient consent, and does not require medical referral.
Diagnostic confirmation from a medical institution is re-
quired to be registered. Questionnaires with prepaid
postage were initially sent to the 60 persons with HSP
aged 30 years or older who were registered in Frambu’s
database. Four weeks later, the questionnaire was sent to
235 NASPA members.
Population data from the third wave of the epidemio-
logical survey “Helseundersøkelsen i Nord-Trøndelag”
(HUNT3) was used as control group. HUNT3 is a com-
prehensive Norwegian survey of health conditions. All
inhabitants in Nord-Trøndelag County aged 19 years
and above were mailed questionnaires and an invitation
to a clinical examination. HUNT3 (2006–2008) com-
prises the latest population data, providing recent results
for gender and age groups comparable to our respon-
dents. The control group comprised 46,293 persons, i.e.,
all participants aged 30 years and older from the third
wave of HUNT3.
The HSP and control samples were not matched be-
yond age and gender, to examine differences in demo-
graphic variables between the HSP sample and controls
(e.g., marital and educational status). The study was
planned and performed in cooperation with NASPA and
approved by The Regional Committee for Medical and
Health Research (REK East).
Measures
The questionnaire comprised three main parts: (a) back-
ground and demographic information; (b) health-related
questions specific to the HSP diagnosis; and (c) excerpts
from HUNT3, covering several themes in relation to
mental and physical health and functioning (i.e., life sat-
isfaction, mental wellbeing, pain, sleep, diseases, oral
health, gastrointestinal problems, medication use, phys-
ical activity, frequency of falling, social support, as well
as health service use and satisfaction).
Most themes were covered by a few categorical ques-
tions best reported as frequencies rather than as scales.
Fjermestad et al. Orphanet Journal of Rare Diseases  (2016) 11:98 Page 2 of 9
The sleep problems scale had unsatisfactory inter-item
reliability, and the items were thus considered separately.
We computed combined scale variables with satisfactory
inter-item reliability for three themes (Mental wellbeing,
α = .79; Memory, α = .88; Gastrointestinal problems,
α = .67). Furthermore, we computed a Total physical im-
pact variable by adding participants’ scores (No impact to
Major impact) on the 11 symptoms, representing a 12 to
36-range scale from lowest to highest impact.
HSP-specific questions were compiled by the authors
on the basis of current medical knowledge on HSP, in
co-operation with board members of NASPA. Four
board members of NASPA provided feedback on a pre-
liminary version of the questionnaire. This feedback in-
fluenced selection of both HSP-specific questions and
HUNT3 variables. In co-operation with NASPA we
decided not to include questions on typical symptoms of
complex HSP, to reduce the burden on participants.
Controls were not presented with the HSP-specific
questions.
Data analysis
Data were analyzed using IBM SPSS version 21.0. Com-
parisons between the HSP sample and controls were
done by calculating Pearson’s chi-square to estimate
whether frequencies were significantly different between
the samples. To reduce expected frequencies below 5,
some response categories were combined for some
variables (e.g., often and very often) when required.
When relevant, effect size differences were calculated as
MHSP sample - Mcontrols/pooled standard deviation. We
used the following cut off values to interpret magnitude
of effect sizes: d = 0.2 (small), d = 0.5 (medium), and d =
0.8 (large) [23]. Effect sizes were only calculated if differ-
ences were significant at or below the p = .05-level.
Results
The response rate from patients in the Frambu database
was 80 %. The exact response rate from the NASPA
register is not known, as NASPA also has members with
hereditary ataxias, who were asked to ignore the request.
The response rate in HUNT3 was 54 %.
Comparison of samples
The mean age between the HSP sample and controls
was comparable (MHSP = 57.7 years, SD = 11.5 vs. Mcon-
trols = 55.9 years, SD = 14.0, d = 0.13). The gender distri-
bution between the HSP sample and controls was not
significantly different (female ratioHSP = 53.7 % vs. female
ratiocontrols = 54.2 %; (χ
2 (1) = 0.011, p = .916).
Within the HSP sample, participants recruited from
NASPA were significantly older than participants re-
cruited from Frambu (MNASPA = 59.7 years, SD = 11.5 vs.
MFrambu = 54.6 years, SD = 10.9, d = 0.46). The gender
distribution was not significantly different dependent on
recruitment setting (female ratioNASPA = 50.8 % vs. fe-
male ratioFrambu = 59.5 %; (χ
2 (1) = 0.788, p = .354).
Background information
See Table 1 for information on marital status, educa-
tional level, and main source of income for the HSP
sample. Within the HSP sample, women more frequently
reported to be married or cohabiting compared to men
(χ2 (1) = 4.585, p < .05). Apart from this, there was no
gender difference in the HSP sample in terms of back-
ground variables. In the HSP sample, 15.7 % reported to
live with children.
HSP compared to controls
Comparing the HSP sample to controls, there were
significant differences in family status (χ2 (3) = 1711.46,
p < .001). Participants in the HSP sample less frequently
lived with a partner/spouse (χ2 (1) = 5.37, p < .05), and
more frequently lived alone (χ2 (1) = 32.07, p < .001).
There was no difference between the samples in fre-
quency of living with parents (χ2 (1) = 0.21, p = .647) or
children (χ2 (1) = 0.51, p = .477).
Overall, the HSP sample reported lower life satisfac-
tion, lower mental wellbeing and lower social support, as
well as poorer memory and sleep, compared to controls.
Furthermore, the HSP sample more frequently reported
musculoskeletal pain, constipation, and urinary incontin-
ence compared to controls. There was no difference be-
tween samples in frequency of physical activity and
alcohol and tobacco use. A detailed summary of the
main findings regarding the HSP sample compared to
controls is presented in Table 2.
HSP-specific results
The majority (58 %) reported that HSP was genetically
confirmed. A quarter (24 %) reported that this was not
the case, while 16 % reported they did not know. The
majority (66 %) reported that one or more family mem-
bers also had HSP. With multiple categories possible,
the most frequently reported family members with HSP
were siblings (n = 35), mothers (n = 25), children (n =
22), and fathers (n = 19).
Overall impact of HSP
Participants rated the overall impact of having HSP on a
scale from 0 to 10, with 10 indicating the most negative
impact. The mean rating was 7.2 (SD = 2.2), with males
(m) rating a higher overall negative impact than females
(f ) (Mm = 7.8, SDm = 2.1; Mf = 6.7, SDf = 2.3; t = 2.399,
p < .05; d = 0.50). The correlation between age and
HSP impact was non-significant (r = .15, ns).
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Physical impact
Figure 1 shows the percentages of participants who rated
“major impact” of 11 physical symptoms. There was no
gender difference except for the frequency of reporting
impact on sexual function, which was more often re-
ported by males with HSP compared to females with
HSP (χ2 (1) = 10.299, p < .001).
The mean score for all participants on the 12–36
range physical impact scale was 24.0 (SD = 4.8). There
was no significant gender difference (Mm = 24.7, SDm =
5.2; Mf = 23.4, SDf = 4.4; t = 1.447, ns). Forty-two women
responded to whether physical symptoms got worse with
menstruation (including in retrospect for those beyond
menstrual age). Of these 42 women, eight confirmed a
low degree of worsening, three confirmed high degree of
worsening, while 31 rated no worsening.
Mobility and activities of daily living
In terms of mobility, 35 % reported to walk without aids
outdoors, while 56 % reported to walk without aids
indoors. Around a third (31 %) reported to use a
wheelchair indoors, while 45 % reported to use a wheel-
chair outdoors. The majority (80 %) confirmed having a
driver’s license. See Table 3 for overview of the percent-
age of participants who reported incapability to conduct
activities of daily living (ADL) without assistance.
We computed a total activities of daily living (ADL)
score by adding the number of activities participants
reported not being able to perform. The mean score was
2.7 activities, (SD = 3.6, range 0 to 16). Men reported
more activities they could not perform without assist-
ance compared to women (Mm = 3.5, SDm = 4.3; Mf = 2.0,
SDf = 2.9; t = 2.101, p < .05; d = 0.16). Fisher’s exact tests
showed that the two activities men reported to be able
to perform less frequently compared to women were
simple household chores (p < .05) and laundry (p < .001).
Frequency of falling
In the HSP sample, 47 % reported to have fallen in the
last 3 months. There was no gender difference in fre-
quency of falling (χ2 (1) = 1.375, ns). There were no sig-
nificant age difference between those who confirmed
having fallen and those who did not (t = 0.588, ns).
HSP sample medication use
In the HSP sample, 15 % reported using Botox injec-
tions, 10 % reported using a baclofen pump, and 33 %
reported taking oral spasmolytics. Of these, the percent-
ages of participants reporting having some or large effect
of the medication were 83 % for Botox, 86 % for baclo-
fen pump, and 82 % for oral spasmolytics.
Gender differences within the HSP sample
There were no significant gender differences on any of
the variables shown in Table 2, except overall life satis-
faction. Males rated significantly lower life satisfaction
Table 1 Background variables for the HSP sample
Total Men Women
(N = 107a) (N = 49) (N = 58)
Marital status
Single 23.1 % 30.6 % 17.2 %
Married/cohabiting 54.9 % 44.9 % 65.5 %b
Divorced 15.7 % 18.4 % 13.8 %
Widowed 4.6 % 6.1 % 3.4 %
Education level
Primary school 11.1 % 6.1 % 15.8 %
Secondary school 34.3 % 34.7 % 33.3 %
High school 23.1 % 22.4 % 24.6 %
<3years University degree 15.7 % 16.3 % 15.8 %
>3years University degree 13.9 % 20.4 % 8.8 %
Other 0.9 % 0 % 1.8 %
Main source of income
Paid salary 18.5 % 14.3 % 22.4 %
Disability pension 53.7 % 51.0 % 55.2 %
Retirement pension 24.1 % 30.6 % 19.0 %
Sickness benefits 2.8 % 2.0 % 3.4 %
Body mass index (BMI) M = 25.5 (SD = 4.5) M = 26.2 (SD = 4.0) M = 24.9 (SD = 4.8)
Note. aBacground information was missing for one participant. bGender difference was significant at the .05-level (Pearson’s chi-square)
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Table 2 HSP sample compared to controls: Overview of main results
Main finding HSP sample HSP sample compared to controls
Overall life satisfaction
M = 3.6 (SD = 1.2, range 1 to 7)a HSP sample poorer (χ2 (1) = 210.20, p < .001).
Mental wellbeing
M = 11.4 (SD = 3.3, range 6 to 21) HSP scored lower than controls on 5 of 6 items (χ2 (1) range
13.38 to 65.95, all p < .001).
Memory
M = 15.2 (SD = 4.0, range 9 to 27) HSP more frequently reported problems on 6 of 9 items
(χ2 (1) range 4.21 to 26.306, all p < .05)
Sleep
Percentage of participants who rated several times a week: daytime
drowsiness: 35 %; frequent night awakenings 36 %; trouble falling
asleep 28 %; waking up early 19 %.
HSP reported more sleep problems on all items (χ2 (1)
range 6.39 to 59.26, all p < .05).
Pain
70 participants (64.8 %) confirmed chronic pain of >3 months duration
in the past year. Most frequent pain sites: feet, knees, lower back, and hips.
HSP confirmed more frequent musculoskeletal pain
(χ2 (1) = 6.51, p < .05). HSP confirmed more frequent
pain in the lower body pain sites (χ2 (1) range 5.067
to 61.636, all p < .05). Controls more frequent pain in
the upper body pain sites (χ2 (1) range 7.817 to 26.141,
all p < .05).
Comorbid disease prevalence
Most frequently reported diseases were mental health problems 19 %;
osteoarthritis 14 %; hand eczema 11 %; psoriasis 10 %; asthma 8 %;
and brain hemorrhage 7 %.
HSP more frequently reported brain hemorrhage
(χ2 (1) = 5.284, p < .05) and psoriasis (χ2 (1) = 4.324, p < .05).
Gastrointestinal problems
Percentage of participants who reported much problems: constipation 14 %;
alternating constipation and diarrhea 7 %; bloating 7 %; heartburn 6 %;
diarrhea; and nausea 0 %. 11 % confirmed fecal incontinence weekly or daily.
HSP more frequently reported much problems on alternating
constipation and diarrhea (χ2 (1) = 9.163, p < .05) and
constipation (χ2 (1) = 11.032, p < .05). HSP more frequently
reported fecal incontinence (χ2 (1) = 26.253, p < .001).
Urinary problems
52 % confirmed urinary incontinence HSP more frequently reported urinary incontinence
(χ2 (1) = 5.427, p < .05)
Oral health
67 % rated their oral health as good or very good, while 13 % rated their
oral health as poor or very poor.
No difference, but HSP reported more frequent dental
visits during the last year compared to controls
(χ2 (1) = 4.466, p < .05).
Physical activity
Reported frequency of physical activity: daily 18 %; 2–3 times pr.
week 33 %; once a week 22 %; less than once a week 14 %;
and never 11 %.b
No difference in frequency. HSP spent more hours
sitting daily compared to controls (MHSP = 9.0 vs.
Mcontrols = 5.7, effect size difference d = 1.18).
Medication use
Percentage of participants who reported taking nonprescription
medicines 1–3 times weekly: for general pain 31 %; for constipation
17 %; for headache 16 %; and for heartburn 10 %.c
HSP more frequently reported taking medication for
constipation (χ2 (1) = 30.685, p < .001) and general pain
(χ2 (1) = 4.068, p < .05). Otherwise no difference.
Alcohol and tobacco use
Percentage of participants who reported drinking alcohol at least




Percentage of participants who confirmed practical support 82 %
and emotional support 80 %d
HSP reported lower practical support (χ2 (1) = 36.07,
p < .001) and lower emotional support (χ2 (1) = 13.59,
p < .001).
Note. M mean, SD standard deviation. No age or gender difference unless indicated. a = males reported higher impact than females. b = older participants spent
more hours sitting daily. c = older participants took more laxatives. d = older participants reported lower emotional support
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compared to females (Mm = 3.9, SD = 1.1, Mf = 3.3,
SDf = 1.3; t = −2.157, p < .05; d = 0.40).
Pure versus complex HSP
The majority of the HSP sample (69 %) reported to be
“mainly affected in the lower body”, which was used a
proxy for pure HSP. We examined whether there were
significant differences based on this distinction, and
found that this was the case for three variables. Partici-
pants with proxy complex HSP reported a higher overall
impact of HSP (Mpure = 6.9, SDpure = 2.1 vs. Mcomplex =
8.1, SDcomplex = 2.3; t = 2.669, p <. 05; d = 0.55).
Furthermore, those with proxy complex HSP were diag-
nosed at a later age compared to those with proxy pure
HSP (Mpure = 40.4 years, SDpure = 15.8 vs. Mcomplex =
48.7 years, SDcomplex = 15.4; t = 2.435, p <. 05; d = 0.51).
Fig. 1 Percentage of 108 persons with HSP reporting “major impact” of physical complaints. Note. *Significant gender difference (p < .001)
Table 3 Ability to perform activities of daily living among 108 persons with HSP
Activity Percentage who confirmed not being able to perform activity without assistance
Total sample Pure HSP Complex HSP
N = 108 N = 75 N = 32
Walking indoors, ground floor 14 % 12 % 16 %
Visit the toilet 6 % 4 % 6 %
Body washing 5 % 1 % 9 %
Showering/bathing 8 % 4 % 16 %a
Dress-undress 5 % 3 % 6 %
Get out of bed/get into bed 5 % 3 % 6 %
Eating 2 % 1 % 0 %
Preparing warm meals 15 % 8 % 28 %a
Easy household chores 13 %b 8 % 22 %a
Complex household chores 46 % 37 % 66 %a
Do the laundry 19 %b 11 % 34 %a
Grocery shopping 21 % 13 % 38 %a
Paying bills 12 % 7 % 22 %a
Taking medications 5 % 3 % 6 %
Getting outside daily 13 % 9 % 19 %
Taking the bus 51 % 41 % 72 %a
Driving 12 % 9 % 19 %a
Note. aParticipants with complex HSP significantly more frequently confirmed not being able to perform activity unassisted (all χ2 (1) >3.935, all p < .05). bMen
significantly more frequently confirmed not being able to perform activity unassisted (all p < .05)
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Finally, those with proxy complex HSP reported more
ADL that they were not able to perform without assist-
ance (Mpure = 1.9 activities, SDpure = 2.9 vs. Mcomplex = 4.4
activities, SDcomplex = 4.0; t = 3.439, p <. 001; d = 0.74).
Significantly fewer participants with proxy complex HSP
reported to have a driver license compared to those with
proxy pure HSP (χ2 (1) = 15.867, p < .001). See Table 3
for differences between the pure and complex types in
terms of ability to perform activities of daily living.
There was no difference between the proxy pure/com-
plex types in terms of age, total body impact, pain, mental
well-being, memory, gastrointestinal/urinary problems,
number of additional diseases, BMI, or physical activity.
Correlations between variables in the HSP sample
See Table 4 for correlations between the scale variables
for the HSP sample. Note that apart from age of onset,
age was only significantly correlated with physical impact,
and no other health variable. In fact, physical impact was
the factor with most significant correlations with other
health variables.
Discussion
The present report is a comprehensive survey of mul-
tiple health variables in a large sample of adults aged
30 years and older with HSP. Several variables were
drawn from HUNT3, a large population survey, allowing
comparison of results from the HSP sample to popula-
tion controls. Compared to controls, persons with HSP
reported lower scores on life satisfaction, mental
wellbeing, as well as perceived practical and emotional
support. Furthermore, compared to controls, persons
with HSP reported more problems with memory, sleep,
gastrointestinal and urinary function, and pain in the
lower body. Our results showed persons with HSP ex-
perience large total physical impact of their disorder.
This total impact was significantly correlated with age,
mental wellbeing, memory problems, gastrointestinal
problems, extent of pain, number of co-morbid diseases,
and life satisfaction. Thus, the disease burden for adults
with HSP is multifaceted, and involves problem areas
not previously documented.
Gastrointestinal problems for persons with HSP have
previously been documented in a Dutch study, in which
combined fecal and urinary incontinence was identified
among seven of 18 patients aged 13 to 46 years with com-
plex HSP, specifically SPG11 mutation [24]. In our HSP
sample, gastrointestinal problems were significantly corre-
lated with perceived quality of life. This in line with findings
from a review of adult patients with central neurological
disorders like Parkinson’s disease, Alzheimer’s disease and
multiple sclerosis, in which impaired bowel function was
shown to increase anxiety and reduce quality of life in [25].
The identified gastrointestinal problems for persons with
HSP warrant further research and clinical attention.
Our results also showed considerable impact on activ-
ities of daily living for persons with HSP. Over half the
sample reported not being able to take the bus, and
nearly half the sample reported not being able to do
more than basic house chores. We were surprised to
find that age was only correlated with total physical im-
pact and ability to perform ADL, and not with any other
health-related variable. This implies that the burden of
disease experienced by adults with HSP is considerable
across the lifespan. Importantly, older participants re-
ported less practical support compared to younger par-
ticipants, possibly indicating a particular need for the
older HSP group.
Table 4 Correlations between variables among 108 adults with HSP
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
1. Age 1
2. Age of onset .60** 1
3. Education -.16 -.22* 1
4. BMI -.19 -.20* .11 1
5. Overall HSP impacta .15 .08 .03 -.04 1
6. Physical impacta .25* .04 -.07 .02 .37** 1
7. Mental wellbeing .03 -.01 -.22* -.14 .22* .34** 1
8. Life satisfactiona .03 .05 -.23* -.12 .54** .39** .57** 1
9. Physical activity -.06 .07 .14 -.07 -.08 -.15 -.14 -.06 1
10. Memory problemsa .13 .15 -.16 .04 .13 .28** .30** .19 -.03 1
11. Gastrointestinal problemsa -.02 -.02 -.07 -.09 .08 .36** .16 .25* -.07 .33** 1
12. Number of diseases .13 .01 -.11 .05 .09 .23* -.01 -.01 -.27** .11 .16 1
13. Paina -.05 -.00 -.00 .02 .26* .48** .22 .27* -.12 .22* .29* .18 1
14. Activities of daily livinga .40** .21 -.06 -.22 .23 .21 .14 .18 -.10 .29* .18 .23 .29*
Note. aHigher scores indicate more problems. *Correlation is significant at the p < .05-level. **Correlation is significant at the p < .001 level
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We uncovered some important gender differences
within the HSP sample. Specifically, men reported sig-
nificantly higher overall impact of HSP, higher impact on
sexual function, more ADL they could not perform with-
out assistance, and lower overall life satisfaction com-
pared to women with HSP. Possibly, the features of HSP
are in larger conflict with typical gender expectations for
men compared to women, as the stereotypical and
traditional Western male gender role ideologies tend to
favor physical capabilities as well as personal autonomy
[26]. On the other hand, we did not find gender differ-
ences that could be expected based on previous findings,
such as in terms of perceived social support, which has
been shown to be lower among males [27]. In sum, our
results indicate that men with HSP represent a particu-
larly vulnerable group in terms of overall HSP impact
and quality of life.
The current study has some limitations. First, we rely
on self-reported diagnosis and not genetic confirmation.
Although we have no reason to believe non-HSP pa-
tients responded, we cannot rule out this possibility.
Second, beyond self-reported memory problems we did
not assess cognitive abilities among participants. Cogni-
tive deficits are documented among HSP patients and
may impact both symptoms and self-report accuracy.
Third, relying on self-report excluded possibilities of
cross-referencing and validating data with medical re-
cords. Fourth, we used “only lower body affect” as a
proxy for pure HSP. In a questionnaire-based study, this
was perceived to be the most reliable distinction be-
tween pure and complex. The prevalence of the two
forms in our study is in accordance with a previous
survey [21]. However, the validity of this distinction is
uncertain, so our findings regarding differences between
pure and complex HSP should be interpreted with cau-
tion. Finally, it is likely that some persons in the control
group experience neuromotor problems, but due to the
substantial size of the control group this is unlikely to
have influenced results.
In spite of these limitations, the considerable sample
size, the inclusion of a large population-based control
group, and the involvement of a patient advocacy
organization in the development of measures, indicate
the results of the present report represent important and
relevant insights into self-perceived functioning in pa-
tients with HSP. Future studies should examine the per-
spective of the providers of health services to patients
with HSP, to identify potential knowledge gaps about
this patient population.
Conclusion
The main clinical implications of the present report are
that HSP patients should be assessed on a wide range of
areas of functioning. Men with HSP and persons with
complex HSP may be in particular need of such inter-
vention. Mental health was significantly correlated with
physical impact and overall impact of HSP. Although
our design prevents us from examining causality, health
professionals should also assess mental health in patients
with HSP. Future studies should examine longitudinal
development of the problem areas identified for patients
with HSP, to provide better standards for care.
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